About Us


Hagop Youssoufian, M.D.


Hagop Youssoufian, M.D., has been C4 Therapeutics’ interim chief medical officer (CMO) since February 2023. Dr. Youssoufian is a physician-scientist with more than 25 years of experience in drug development working with seed-stage ventures to multi-national biotech and pharmaceutical corporations. After a successful academic career as a clinician, teacher and NIH-funded investigator, he held increasingly senior roles in clinical and translational science at Bristol-Myers Squibb (Head of Experimental Medicine), Sanofi Aventis (Distinguished Scientist), ImClone (CMO), Ziopharm Oncology (President of Research & Development and CMO), Progenics (Executive Vice President of Research & Development) and BIND (CMO). Dr. Youssoufian supported or led the development and approval of a number of medicines including Sprycel, Taxotere, Erbitux, Cyramza, Lartruvo and Copiktra. He is an elected member of the American Society for Clinical Investigation, the recipient of many national and international awards, and the author of more than 100 publications. Dr. Youssoufian has served as a member of our clinical advisory board since 2021. He received a B.S. in biology from Boston College and M.Sc./M.D. from University of Massachusetts Medical School, followed by fellowships at Johns Hopkins, Harvard and MIT.